SNSS

Sunesis Pharmaceuticals, Inc. Press Releases

$2.53
*  
0.05
1.94%
Get SNSS Alerts
*Delayed - data as of Dec. 19, 2014  -  Find a broker to begin trading SNSS now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Sunesis Announces Presentation of Positive Updated Results from Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASH Annual Meeting
12/8/2014 1:30:00 PM - GlobeNewswire


Sunesis Pharmaceuticals Announces Presentation of Results From Phase 3 VALOR Trial at ASH Annual Meeting
12/7/2014 12:30:00 PM - GlobeNewswire


Sunesis Pharmaceuticals to Host Conference Call and Slide Webcast Tuesday, December 9 Following Presentation of Phase 3 VALOR Trial Results at ASH Annual Meeting
12/2/2014 7:00:00 AM - GlobeNewswire


Sunesis Announces Publication of REVEAL-1 Trial Results in the British Journal of Haematology
11/24/2014 7:00:00 AM - GlobeNewswire


Sunesis Announces Publication of Vosaroxin Phase 1b/2 AML Trial Results in Haematologica
11/19/2014 7:00:00 AM - GlobeNewswire


Sunesis Pharmaceuticals Announces Late-Breaking Presentation of Phase 3 VALOR Trial at ASH Annual Meeting
11/17/2014 9:05:00 AM - GlobeNewswire


Sunesis Pharmaceuticals Reports Third Quarter 2014 Financial Results and Recent Highlights
11/10/2014 7:00:00 AM - GlobeNewswire


Sunesis to Present at Upcoming Investor Conferences
11/5/2014 7:00:00 AM - GlobeNewswire


Sunesis to Host Conference Call on November 10th to Discuss Third Quarter 2014 Financial Results and Recent Highlights
11/3/2014 7:00:00 AM - GlobeNewswire


Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia
10/6/2014 6:30:00 AM - GlobeNewswire